This devised hematopoietic cell transplantation-specific comorbidity index (HCT-CI) expands on the original CCI by including newly identified comorbidities and the refinement of comorbidity ...

What makes a patient fit for transplant? To help determine that, Sorror and his colleagues developed the Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI). Originally published in ...

He had one identified comorbidity for malignancy on the HCT-CI score. He was therefore placed in the favorable risk group for tolerating non-myeloablative conditioning and allogeneic transplant. The ...

Measures of risk assessment commonly used to predict HSCT outcomes include the validated hematopoietic cell transplantation-specific comorbidity index (HCT-CI) and Karnofsky performance score.

The other significant risk factors found for CVD were Black race (HR, 1.69; 95% CI, 1.00-2.86), older age at HCT (HR, 1.06; 95% CI, 1.02-1.10), high HCT-comorbidity index (CI) score (HR ...

The Karnofsky Performance Status score exceeded 70 for 83% of those included, with an augmented HCT-CI of 4 or more for 60%. The study population was predominantly white (86%) and black (6%).

The EASIX scoring system should not be used to predict outcomes following allogeneic stem cell transplantation (alloSCT) in patients with myelofibrosis. A new study has found that the ...

the rate was 40% (95% CI, 33% - 47%). Overall, the HCT survivors were 5.6 times more likely to develop a severe/life-threatening condition when compared with age- and sex-matched siblings.